Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer
Phase 2
- Conditions
- Metastatic or relapsed small-cell lung cancer
- Registration Number
- JPRN-C000000130
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
This phase II study showed the favorable efficacy and moderate safety profiles of a topotecan and amrubicin two-drug combination especially in relapsed patients with ED-SCLC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method